The Changing Landscape for HER2+ Advanced Metastatic Breast Cancer

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.

A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.

Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.

Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.

An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.

Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.

Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.

Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.

A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.